Vaxcyte, Inc. — Director's Dealing 2025

Feb 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-02-03

Reporting Person: Wassil Jim (CHIEF OPERATING OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-03	Common Stock	M	8000	$2.42	Acquired	213695	Direct
2025-02-03	Common Stock	S	5314	$85.996	Disposed	208381	Direct
2025-02-03	Common Stock	S	2666	$86.665	Disposed	205715	Direct
2025-02-03	Common Stock	S	20	$87.94	Disposed	205695	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-03	Stock Option (right to buy)	$2.42	M	8000	Disposed	2029-12-16	Common Stock (8000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $85.32 to $86.295. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $86.365 to $87.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F4: Option is fully vested and exercisable.